Is ANAB (AnaptysBio, Inc.) Halal or Haram?

Based on our AAOIFI-standard shariah screening, ANAB is classified as Doubtful. It passed 3 of 4 compliance screens. Some scholars may permit investing with income purification, while others advise avoiding it. We recommend consulting a qualified Islamic scholar before investing in ANAB.

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing therapeutic antibodies for severe inflammatory diseases and immuno-oncology. Its innovative pipeline includes Imsidolimab for dermatological conditions and Rosnilimab, an anti-PD-1 agonist designed to suppress T-cell driven human inflammatory diseases. For Muslim investors, AnaptysBio currently holds a Doubtful shariah compliance status based on AAOIFI standards. While its core biotechnology operations and debt levels easily pass Islamic screening criteria, the company fails the interest income screen, meaning it cannot be considered fully halal at this time. From an Islamic finance perspective, the company boasts an incredibly strong balance sheet with a debt-to-market cap ratio of just 0.5%, well below the 33% limit. Unfortunately, its interest income accounts for 5.75% of its total revenue, pushing it just past the strict 5% threshold allowed for shariah-compliant portfolios. Since the interest income failure is relatively close to the borderline, Muslim investors should keep a close eye on future quarterly reports. If revenue from core operations increases or interest-bearing cash holdings yield less, AnaptysBio could easily transition into a fully compliant status. AnaptysBio, Inc. operates in the Healthcare sector under the Biotechnology industry and is headquartered in San Diego, CA, US. The company is led by CEO Daniel R. Faga and employs approximately 136 people.

ANAB was screened using AAOIFI-based shariah compliance criteria. Four tests are applied: (1) Business Activity — the company's core business must not derive primary income from haram (prohibited) activities such as alcohol, gambling, tobacco, or interest-based finance. (2) Debt-to-Market-Cap — total debt must not exceed 33% of market capitalization. (3) Interest Income — interest income must not exceed 5% of total revenue. (4) Cash & Securities — cash and interest-bearing securities must not exceed 33% of market cap. ANAB passed 3 of these 4 screens.

ANAB was last screened on 2026-04-27. Shariah compliance status can change as companies report new financial data, acquire new businesses, or shift revenue streams. We recommend checking back periodically for the most up-to-date screening results.